Spectrum Fertility Group proudly announces that Dr. Xuelong Yao, Chief Science Officer, has been awarded the prestigious 2024 ASRM Society for Reproductive Biology and Technology (SRBT) Award for his groundbreaking research in embryo quality assessment. Dr. Yao's pioneering work on DNA methylation and the development of the Preimplantation DNA Methylation Screening (PIMS) test has significantly advanced assisted reproductive technology. Additionally, Spectrum Fertility Group is expanding its reach with the opening of a new state-of-the-art fertility lab in metro Washington, D.C., furthering its commitment to providing innovative fertility treatments and comprehensive reproductive health services.
BOSTON, Nov. 3, 2024 /PRNewswire-PRWeb/ -- Spectrum Fertility Group's Chief Science Officer, Dr. Xuelong Yao, Wins Prestigious ASRM SRBT Award for Groundbreaking Research in Embryo Quality Assessment
Spectrum Fertility Group, a leading fertility and reproductive health company based in Boston, MA, is proud to announce that its Chief Science Officer, Dr. Xuelong Yao, has been honored with the 2024 ASRM Society for Reproductive Biology and Technology (SRBT) Award. Dr. Yao received this prestigious accolade for his pioneering paper titled, "A Novel Approach to Assessing Embryo Quality in Assisted Reproductive Technology: DNA Methylation."
Dr. Yao is globally recognized as a leader in epigenetic research and has co-founded the revolutionary Preimplantation DNA Methylation Screening (PIMS) test. The PIMS test, designed to enhance embryo selection in assisted reproductive technology, has recently received its second U.S. patent, adding to a portfolio of eight patents awarded internationally. This innovation underscores Spectrum Fertility Group's commitment to advancing reproductive medicine through cutting-edge research and technology.
In addition to this significant achievement, Spectrum Fertility Group is delighted to announce the opening of its new Spectrum Fertility Lab in metro Washington, D.C. This state-of-the-art facility is dedicated to providing advanced fertility treatments and comprehensive reproductive health services, further expanding Spectrum Fertility's reach and impact in the field of assisted reproduction.
"We are incredibly proud of Dr. Yao's accomplishments and his continued dedication to advancing the science of reproductive health," said Angela Prothmann, CEO of Spectrum Fertility Group. "His work in DNA methylation and embryo quality assessment is transforming the landscape of fertility treatments, and the opening of our new lab in Washington, D.C. marks an exciting expansion of our capabilities to serve more patients."
Dr. Yao's award-winning research and the continuous innovation at Spectrum Fertility Group highlight the company's leadership in reproductive health and its unwavering commitment to improving outcomes for patients worldwide.
For more information about Spectrum Fertility Group and its services, please visit www.spectrumfertility.com or contact [email protected].
About Spectrum Fertility Group
Spectrum Fertility Group, headquartered in Boston, MA, is a pioneering organization in fertility and reproductive health. The company is dedicated to providing innovative fertility treatments and comprehensive reproductive health services. Through cutting-edge research, such as the development of the PIMS test, Spectrum Fertility Group continues to lead advancements in assisted reproductive technology.
Media Contact:
Victor Thomas
Spectrum Fertility Group
Note to editors: Interviews with Dr. Xuelong Yao are available upon request.
Media Contact
Victor Thomas, Spectrum Fertility Group, 1 703-795-4740, [email protected], www.spectrumfertility.com
SOURCE Spectrum Fertility Group
Share this article